Telemark Asset Management LLC Has $2.23 Million Stake in Biodesix, Inc. $BDSX

Telemark Asset Management LLC lowered its stake in shares of Biodesix, Inc. (NASDAQ:BDSX) by 20.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 327,824 shares of the company’s stock after selling 86,300 shares during the period. Telemark Asset Management LLC owned approximately 4.12% of Biodesix worth $2,229,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. XTX Topco Ltd boosted its stake in Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Biodesix in the 3rd quarter worth approximately $113,000. Oracle Investment Management Inc. purchased a new position in shares of Biodesix in the 3rd quarter worth approximately $113,000. Geode Capital Management LLC boosted its stake in shares of Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after buying an additional 2,235 shares during the last quarter. Finally, Aberdeen Group plc purchased a new position in Biodesix in the fourth quarter valued at approximately $1,784,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Weiss Ratings downgraded Biodesix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 18th. Canaccord Genuity Group upped their price objective on Biodesix from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Finally, William Blair upgraded Biodesix from a “market perform” rating to an “outperform” rating in a research note on Friday, February 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $22.00.

Biodesix Price Performance

Biodesix stock opened at $15.46 on Friday. Biodesix, Inc. has a 12 month low of $5.00 and a 12 month high of $20.21. The company has a current ratio of 2.82, a quick ratio of 2.82 and a debt-to-equity ratio of 5.09. The business’s 50 day simple moving average is $14.02 and its 200 day simple moving average is $11.69. The company has a market cap of $160.17 million, a price-to-earnings ratio of -3.81 and a beta of 0.59.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Monday, May 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.32. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. The business had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $23.12 million. Sell-side analysts forecast that Biodesix, Inc. will post -2.99 EPS for the current year.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.